A Phase 1 interventional study of Tocilizumab in Giant Cell Arteritis, sponsored by Hoffmann-La Roche. Completed at 2 sites in Switzerland. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2021-12-22.
Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing tocilizumab in Giant Cell Arteritis — 2 open to participants now, 3 under way, 1 of them phase 3. tocilizumab · Giant Cell Arteritis.
Among the 12 studies testing tocilizumab in Giant Cell Arteritis, this one is the 9th largest by enrollment, is the only one that started in 2019, is one of 2 in phase 1, and was the 7th registered.
149 studies on the registry are indexed under Giant Cell Arteritis; 50 are open to participants now.
Browse Giant Cell Arteritis studies →2 of the 12 studies testing tocilizumab in Giant Cell Arteritis are open now, in 1 country. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 50+
NYU Langone Health · Sites in United States
Ages 18+
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 36 Giant Cell Arteritis studies recruiting now, 34 (94%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 3 · Phase 4 2
First in 2011; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 64 across 65 interventional studies indexed under Giant Cell Arteritis.
Median enrollment 44 across the 12 interventional studies. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 12 have an industry lead sponsor. The 9 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 4 studies filed under Giant Cell Arteritis — fewer than ten, so there is no comparison to draw.
1 of the studies testing tocilizumab in Giant Cell Arteritis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07108387National Institute of Allergy and Infectious Diseases (NIAID)Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis | 2027-06-11 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing tocilizumab in Giant Cell Arteritis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the pharmacokinetics, pharmacodynamics, and safety of two dose levels of tocilizumab (TCZ) administered by intravenous (IV) infusion every 4 weeks (Q4W) to participants with giant cell arteritis (GCA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive up to 6 doses of Dose 1 of TCZ IV Q4W followed by up to 6 doses of Dose 2 of TCZ IV Q4W.
Drug: Tocilizumab
TCZ will be administered by IV infusion at two dose levels Q4W. The maximum dose of TCZ that will be administered is 800 mg. The dose of TCZ infusion will be calculated on the basis of body weight measured prior to each infusion.
Also known as: RoActemra/Actemra
Maximum Serum Concentration (Cmax) of TCZ
Time frame: Baseline; Weeks 4, 8, 12, 16-24
Trough Serum Concentration (Ctrough) of TCZ at Steady State
Time frame: Baseline; Weeks 4, 8, 12, 16-24
Area Under the Concentration-Time Curve Over the Dosing Interval of 4 Weeks (AUC4weeks) of TCZ at Steady State
Time frame: Baseline; Weeks 4, 8, 12, 16-24
Percentage of Participants With Adverse Events
Time frame: Baseline - Day 151
Serum Concentration of Interleukin-6 (IL-6)
Time frame: Baseline; Weeks 12, 16, 20, 24
Serum Concentration of Soluble Interleukin-6 Receptor (sIL-6R)
Time frame: Baseline; Weeks 12, 16, 20, 24
Serum Concentration of C-Reactive Protein (CRP)
Time frame: Baseline; Weeks 4, 8, 12, 16-24
Erythrocyte Sedimentation Rate (ESR)
Time frame: Baseline; Weeks 4, 8, 12, 16-24
| Milestone | TCZ IV Q4W |
|---|---|
| Started | 24 |
| Completed | 22 |
| Not completed | 2 |
| Withdrew: Adverse event | 1 |
| Withdrew: Withdrawal by subject | 1 |
| Milestone | TCZ IV Q4W |
|---|---|
| Started | 22 |
| Completed | 22 |
| Not completed | 0 |
| ug/mL | TCZ IV Q4W 7 mg/kg | TCZ IV Q4W 6 mg/kg |
|---|---|---|
| Maximum Serum Concentration (Cmax) of TCZ | 197 (118 to 352) | 178 (115 to 320) |
| ug/mL | TCZ IV Q4W 7 mg/kg | TCZ IV Q4W 6 mg/kg |
|---|---|---|
| Trough Serum Concentration (Ctrough) of TCZ at Steady State | 37.2 (6.59 to 69.0) | 22.7 (3.38 to 54.5) |
| day*ug/mL | TCZ IV Q4W 7 mg/kg | TCZ IV Q4W 6 mg/kg |
|---|---|---|
| Area Under the Concentration-Time Curve Over the Dosing Interval of 4 Weeks (AUC4weeks) of TCZ at Steady State | 2130 (1120 to 4300) | 1610 (921 to 3070) |
| Percentage of Participants | TCZ IV Q4W 7 mg/kg | TCZ IV Q4W 6 mg/kg |
|---|---|---|
| Percentage of Participants With Adverse Events | 79.2 | 40.9 |
| pg/mL | TCZ IV Q4W 7 mg/kg | TCZ IV Q4W 6 mg/kg |
|---|---|---|
| Baseline | 57.80 ± 61.149 | 39.46 ± 25.989 |
| Week 12 | 56.03 ± 84.988 | 49.73 ± 81.718 |
| Week 16 | 97.57 ± 277.409 | 43.04 ± 54.232 |
| Week 20 | 38.11 ± 21.147 | 46.97 ± 61.454 |
| Week 24 | 111.00 ± NA | — |
| ng/mL | TCZ IV Q4W 7 mg/kg | TCZ IV Q4W 6 mg/kg |
|---|---|---|
| Baseline | 665.8 ± 153.81 | 671.3 ± 152.69 |
| Week 12 | 680.8 ± 183.84 | 670.9 ± 175.92 |
| Week 16 | 654.6 ± 173.26 | 651.7 ± 136.95 |
| Week 20 | 663.8 ± 147.92 | 690.0 ± 215.91 |
| Week 24 | 519.0 ± NA | — |
| mg/L | TCZ IV Q4W 7 mg/kg | TCZ IV Q4W 6 mg/kg |
|---|---|---|
| Baseline | 0.615 ± 1.1645 | 0.356 ± 0.2486 |
| Week 4 | 0.511 ± 0.7538 | 0.591 ± 1.0646 |
| Week 8 | 0.426 ± 0.3687 | 0.403 ± 0.3217 |
| Week 12 | 0.467 ± 0.5694 | 0.359 ± 0.2585 |
| Week 16 | 0.344 ± 0.2795 | 0.382 ± 0.3726 |
| Week 17 | 0.409 ± 0.2533 | 0.409 ± 0.4521 |
| Week 18 | 0.374 ± 0.2994 | 0.389 ± 0.3168 |
| Week 19 | 0.387 ± 0.2801 | 0.388 ± 0.3348 |
| Week 20 | 0.340 ± 0.2172 | 0.416 ± 0.2938 |
| Week 21 | 0.200 ± 0.0000 | — |
| Week 22 | 0.200 ± 0.0000 | — |
| Week 23 | 0.203 ± 0.0058 | — |
| Week 24 | 0.200 ± 0.0000 | — |
| mm/h | TCZ IV Q4W 7 mg/kg | TCZ IV Q4W 6 mg/kg |
|---|---|---|
| Baseline | 6.1 ± 6.72 | 5.6 ± 5.01 |
| Week 4 | 4.7 ± 3.38 | 5.6 ± 4.11 |
| Week 8 | 7.2 ± 12.25 | 5.0 ± 3.13 |
| Week 12 | 5.9 ± 5.30 | 6.5 ± 5.27 |
| Week 16 | 5.9 ± 4.56 | 5.1 ± 4.32 |
| Week 17 | 5.2 ± 3.84 | 5.0 ± 4.64 |
| Week 18 | 4.4 ± 3.99 | 4.8 ± 3.01 |
| Week 19 | 4.3 ± 2.64 | 5.0 ± 5.20 |
| Week 20 | 7.1 ± 6.19 | 5.6 ± 5.04 |
| Week 21 | 4.5 ± 3.54 | — |
| Week 22 | 5.3 ± 3.79 | — |
| Week 23 | 4.0 ± 3.00 | — |
| Week 24 | 3.7 ± 1.53 | — |
Collected over Baseline - Day 151. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TCZ IV 7 mg/kg Q4W | 0/24 (0%) | 3/24 (12.5%) | 6/24 (25%) |
| TCZ IV 6 mg/kg Q4W | 0/22 (0%) | 1/22 (4.5%) | 3/22 (13.6%) |
| Event | TCZ IV 7 mg/kg Q4W | TCZ IV 6 mg/kg Q4W |
|---|---|---|
| Vertigo positionalEar and labyrinth disorders | 0/24 | 1/22 |
| Lower gastrointestinal haemorrhageGastrointestinal disorders | 1/24 | 0/22 |
| Pneumonia pneumococcalInfections and infestations | 1/24 | 0/22 |
| Aortic aneurysm ruptureVascular disorders | 1/24 | 0/22 |
| Event | TCZ IV 7 mg/kg Q4W | TCZ IV 6 mg/kg Q4W |
|---|---|---|
| NasopharyngitisInfections and infestations | 3/24 | 1/22 |
| Respiratory tract infection viralInfections and infestations | 1/24 | 2/22 |
| Upper respiratory tract infectionInfections and infestations | 2/24 | 0/22 |
| Age, Continuous(Years) | TCZ IV Q4W |
|---|---|
| Mean | 67.9 ± 8.1 |
| Sex: Female, Male(Participants) | TCZ IV Q4W |
|---|---|
| Female | 15 |
| Male | 9 |
| Ethnicity (NIH/OMB)(Participants) | TCZ IV Q4W |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 24 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | TCZ IV Q4W |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 23 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from Aug 2019 to primary completion in Nov 2020, 15 months.
Results were first posted in Dec 2021, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tocilizumab